Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522190 | PMC |
| http://dx.doi.org/10.1186/s12967-021-03106-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Decoding the role of fatty acids and their metabolites in lung fibrosis.
Pol Arch Intern Med
June 2023
Institute of Pharmacology and Toxicology, Goethe University, Frankfurt am Main, Germany
Idiopathic pulmonary fibrosis (IPF) is a progressive and life‑threatening interstitial lung disease of familial or sporadic onset. The incidence and prevalence of IPF range from 0.09 to 1.
View Article and Find Full Text PDFErratum: Addendum: A novel N-Arylpyridone compound alleviates the inflammatory and fibrotic reaction of silicosis by inhibiting the ASK1-p38 pathway and regulating macrophage polarization.
Front Pharmacol
January 2023
Department of Respiratory Medicine, The Second Hospital of Jilin University, Jilin, China.
[This corrects the article DOI: 10.3389/fphar.2022.
View Article and Find Full Text PDFCorrigendum: A novel N-arylpyridone compound alleviates the inflammatory and fibrotic reaction of silicosis by inhibiting the ASK1-p38 pathway and regulating macrophage polarization.
Front Pharmacol
January 2023
Department of Respiratory Medicine, The Second Hospital of Jilin University, Jilin, China.
[This corrects the article DOI: 10.3389/fphar.2022.
View Article and Find Full Text PDFElectronically monitored medication adherence in idiopathic pulmonary fibrosis: prevalence, predictors and outcomes.
ERJ Open Res
July 2022
Dept of Public Health and Primary Care, Academic Centre for Nursing and Midwifery, KU Leuven, Leuven, Belgium.
Medication adherence studies in idiopathic pulmonary fibrosis (IPF) are limited, use cross-sectional designs and report discontinuation rates. We prospectively investigated adherence to pirfenidone in IPF patients using electronic monitoring, which provides insights on whether and when the medication was taken on a day-by-day basis. We investigated the impact of nonadherence on lung function and selected predictors for nonadherence based on the COM-B behavioural model.
View Article and Find Full Text PDF[Smoking-related interstitial lung diseases].
Radiologie (Heidelb)
September 2022
Universitätsklinik für Radiologie und Nuklearmedizin, Medizinische Universität Wien, Währinger Gürtel 18-20, 1090, Wien, Österreich.
Article Synopsis
- - Smoking-related interstitial lung diseases are a diverse group of lung issues that require accurate diagnosis because it affects treatment options and outcomes.
- - Using computed tomography is essential to diagnose these conditions and can help avoid unnecessary lung biopsies; a structured scanning and assessment approach is recommended for best results.
- - Treatment varies based on the disease stage: smoking cessation and steroids are recommended for inflammatory stages, while antifibrotic medications are used for fibrotic changes; cases should involve interdisciplinary discussions for optimal care.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!